128 related articles for article (PubMed ID: 12065877)
1. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells.
Alvarez-Millán JJ; Bocos C; Ferrín V; Lucas AR; Ruibal A; Schneider J
Oncology; 2002; 62(3):286-90. PubMed ID: 12065877
[TBL] [Abstract][Full Text] [Related]
2. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
[TBL] [Abstract][Full Text] [Related]
3. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
Lei H; Hemminki K; Johansson R; Altieri A; Enquist K; Henriksson R; Lenner P; Försti A
Breast Cancer Res Treat; 2008 May; 109(1):165-75. PubMed ID: 17616807
[TBL] [Abstract][Full Text] [Related]
4. Markers of the uPA system and common prognostic factors in breast cancer.
Minisini AM; Fabbro D; Di Loreto C; Pestrin M; Russo S; Cardellino GG; Andreetta C; Damante G; Puglisi F
Am J Clin Pathol; 2007 Jul; 128(1):112-7. PubMed ID: 17580278
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
Błasiak J; Smolarz B
Acta Biochim Pol; 2000; 47(1):191-9. PubMed ID: 10961693
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
Eroglu A; Ulu A; Cam R; Akar N
J BUON; 2006; 11(4):481-4. PubMed ID: 17309181
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer.
Smolarz B; Blasiak J; Kulig A; Romanowicz-Makowska H; Dziki A; Ulanska J; Pander B; Szewczyk T
J Exp Clin Cancer Res; 2001 Jun; 20(2):247-52. PubMed ID: 11484982
[TBL] [Abstract][Full Text] [Related]
9. PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma.
Choi JW; Lee JH; Park HS; Kim YS
J Clin Pathol; 2011 Oct; 64(10):893-7. PubMed ID: 21725041
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
Arch Med Res; 2013 Jan; 44(1):39-45. PubMed ID: 23291383
[TBL] [Abstract][Full Text] [Related]
11. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes.
Nagi DK; McCormack LJ; Mohamed-Ali V; Yudkin JS; Knowler WC; Grant PJ
Diabetes Care; 1997 Aug; 20(8):1304-9. PubMed ID: 9250459
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer.
Su CK; Yeh KT; Yeh CB; Wang PH; Ho ES; Chou MC; Liu KC; Yang SF; Yi YC
J Surg Oncol; 2011 Dec; 104(7):755-9. PubMed ID: 21761413
[TBL] [Abstract][Full Text] [Related]
13. Association of the plasminogen activator inhibitor-1 (PAI-1) Gene -675 4G/5G and -844 A/G promoter polymorphism with risk of keloid in a Chinese Han population.
Wang Y; Long J; Wang X; Sun Y
Med Sci Monit; 2014 Oct; 20():2069-73. PubMed ID: 25350781
[TBL] [Abstract][Full Text] [Related]
14. Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction.
Fu L; Jin H; Song K; Zhang C; Shen J; Huang Y
Chin Med J (Engl); 2001 Mar; 114(3):266-9. PubMed ID: 11780311
[TBL] [Abstract][Full Text] [Related]
15. Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms.
Rossaak JI; Van Rij AM; Jones GT; Harris EL
J Vasc Surg; 2000 May; 31(5):1026-32. PubMed ID: 10805895
[TBL] [Abstract][Full Text] [Related]
16. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
[TBL] [Abstract][Full Text] [Related]
17. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor 1 expression in platelets is not influenced by the 4G/5G promoter polymorphism.
Brogren H; Wallmark K; Jern S; Karlsson L
Thromb Res; 2008; 121(6):793-7. PubMed ID: 17884148
[TBL] [Abstract][Full Text] [Related]
19. Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study.
Abboud N; Ghazouani L; Saidi S; Ben-Hadj-Khalifa S; Addad F; Almawi WY; Mahjoub T
Genet Test Mol Biomarkers; 2010 Feb; 14(1):23-7. PubMed ID: 19929406
[TBL] [Abstract][Full Text] [Related]
20. The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.
Yıldırım ME; Karakuş S; Kurtulgan HK; Kılıçgün H; Erşan S; Bakır S
Biochem Genet; 2017 Aug; 55(4):314-321. PubMed ID: 28303356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
